Jizhen Liang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
FGFR3-TACC3 fusion as a potential primary resistance mechanism to EGFR-TKI in lung adenocarcinoma harboring co-driven mutations: a case report.
Journal: Frontiers in oncology
Published: January 16, 2026
Evaluating the safety and efficacy of combination immune checkpoint inhibitors and chemotherapy treatment in extensive-stage small cell lung cancer.
Journal: Discover oncology
Published: January 27, 2025
Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management.
Journal: Cancer reports (Hoboken, N.J.)
Published: August 28, 2024
Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report.
Journal: Anti-cancer drugs
Published: October 07, 2022
Preliminary Clinical Validation of a Filtration-Based CTC Assay for Tumor Burden and HER2 Status Monitoring in Metastatic Breast Cancer.
Journal: Oncology research and treatment
Published: June 23, 2021
Targeting H19 by lentivirus-mediated RNA interference increases A549 cell migration and invasion.
Journal: Experimental lung research
Published: September 09, 2016
Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Journal: Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Published: March 31, 2015
Reversal effect of BM-cyclin 1 on multidrug resistance by down-regulating MRP2 in BALB/C nude mice bearing C-A120 cells.
Journal: Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
Published: October 12, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026